Cargando…

SAT-439 Impact on Health Care Resources: A Comparison of Costs Following Treatment with Pegvisomant and Somatostatin Analogues Using Optum Claims Database

OBJECTIVES: To estimate the health care resource use (HCRU) and costs for patients diagnosed with acromegaly, following treatment with either pegvisomant, a growth hormone receptor antagonist (GHRA); or a somatostatin analogue (SSA). METHODS: De-identified data from Optum’s Clinformatics(TM) Data Ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kelepouris, Nicky, Emir, Birol, Loftus, Jane, Rubinstein, Emily, King, Donna, McDonald, Margaret
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551765/ http://dx.doi.org/10.1210/js.2019-SAT-439

Ejemplares similares

SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 Naïve Patients with Acromegaly Treated with Pegvisomant
por: Wajnrajch, Michael, et al.
Publicado: (2019)

SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience
por: Wajnrajch, Michael, et al.
Publicado: (2019)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

Safety and Efficacy of Pegvisomant in Pediatric Growth Hormone Excess
por: Tatsi, Christina, et al.
Publicado: (2021)

SAT-434 Patient Reported Outcome Data from Acromegaly Patients Treated with Injectable Somatostatin Analogues in Routine Clinical Practice: Preliminary Results
por: Geer, Eliza, et al.
Publicado: (2019)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

SAT-444 Pituitary Function and the Response to GH Replacement Therapy in Patients with Histiocytosis: Analysis of the Pfizer International Metabolic Database (KIMS)
por: Touraine, Philippe, et al.
Publicado: (2019)

SAT605 Growth Hormone Action In Somatostatin Neurons Regulates Anxiety And Fear Memory
por: dos Santos, Willian O, et al.
Publicado: (2023)

A Rare Case of Thyrotropin Secreting Pituitary Macroadenoma Primarily Treated With Somatostatin Analogue
por: Elsheikh, Arwa Mahmoud, et al.
Publicado: (2021)

OR23-06 Is the Improved Glucose Homeostasis in Patients with Acromegaly Treated with Pegvisomant Caused by Improved Glucagon Secretion?
por: Jørgensen, miss, Nanna Thurmann, et al.
Publicado: (2020)

SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study
por: Gadelha, Mônica, et al.
Publicado: (2019)

SAT-465 Somatostatin Receptor Ligand as Initial Therapy in a Patient with Pituitary Microadenoma and Acromegaly: Temporary Remission and Recurrence
por: Baby, Ann, et al.
Publicado: (2019)

THU008 Coverage Of Education And Training Of Traumatic Brain Injury-induced Growth Hormone Deficiency In US Endocrinology Fellowship Programs
por: Ji Yuen, Kevin Choong, et al.
Publicado: (2023)

SAT628 Effect Of Hepatic Impairment On The Pharmacokinetics, Safety, And Tolerability Of Oral Paltusotine, A Non-peptide, Selective Somatostatin Receptor Subtype 2 Agonist
por: Luo, Rosa, et al.
Publicado: (2023)

THU064 Clinical, Radiological Characteristics And Response To Somatostatin Analogues Of Acromegaly Patients With Different Patterns Of Growth Hormone Response After Oral Glucose Load
por: Godlewska, Magdalena, et al.
Publicado: (2023)

PMON60 Growth Hormone (GH) Replacement Therapy (GHRT) in Patients with Adult GH Deficiency (AGHD) Aged ≥60 Years: Data from NordiNet® IOS and the ANSWER Program
por: Biller, Beverly, et al.
Publicado: (2022)

SAT-313 Synaptojanin 2 Binding Protein Is Required for Efficient Somatostatin Receptor 2A Phosphorylation by G Protein Coupled Receptor Kinases and Signaling to the ERK/MAPK Pathway
por: Carr, Heather S, et al.
Publicado: (2020)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

SAT-430 A Phase 1 Study in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of ONO-5788: A Novel Oral Small Molecule Somatostatin Receptor Type-2 Agonist
por: Kaviya, Arpeat, et al.
Publicado: (2019)

FRI296 Somatostatin Receptor 5 Staining In Prolactinomas
por: Mehta, Sonal, et al.
Publicado: (2023)

Olfactory Neuroblastoma: The Adjunctive Role of Somatostatin Agonists After Surgery
por: Toral, Fernando Pazos, et al.
Publicado: (2021)

Somatostatin, as a Bridge Between the GH-Axis and the Gth-Axis
por: Mizrahi, Naama, et al.
Publicado: (2021)

SUN-LB078 Biochemically Controlled Acromegaly Patients on a Stable Dose of Injectable Somatostatin Analogues in Routine Clinical Practice Still Remain Symptomatic: Preliminary Results from Endocrinology Health Care Professionals
por: Geer, Eliza, et al.
Publicado: (2019)

MON-439 Evaluation of Surgical Resection Goal and Its Relationship to the Extent of Resection and Patient Outcomes in 221 Patients following Transsphenoidal Surgery for Nonfunctioning Pituitary Adenomas: Data from the TRANSSPHER Study
por: Little, Andrew, et al.
Publicado: (2019)

SUN-439 Improvement in Insulin-Like Growth Factor-1 and Clinical Symptoms: Results of an Open-Label, Single-Arm Study of a Human Growth Hormone-Enhancing Amino Acid Supplement
por: Pekarovics, Susan, et al.
Publicado: (2019)

SUN-LB077 Relationship between Responses from Acromegaly Patients Treated with a Stable Dose of Injectable Somatostatin Analogues in Routine Clinical Practice and Their Endocrinology Health Care Professional Regarding Treatment Outcomes: Preliminary Findings
por: Geer, Eliza, et al.
Publicado: (2019)

SAT-451 Acromegaly and Thyroid Cancer
por: Danilowicz, Karina, et al.
Publicado: (2019)

SAT-257 Coexisting Craniopharyngioma and Acromegaly
por: Yang, Almira, et al.
Publicado: (2020)

SAT-273 Case of Mistaken Identity?
por: Pla, Carlos
Publicado: (2020)

SAT-270 Priapism Secondary to Cabergoline
por: Amir, Maryam, et al.
Publicado: (2020)

SAT624 Neurosarcoidosis Presenting With Panhypopituitarism
por: Niedzialkowska, Ewelina Marta, et al.
Publicado: (2023)

MON-467 Expression of Somatostatin Receptors in Aggressive Non-Functioning Pituitary Adenomas
por: Soto, Alfonso, et al.
Publicado: (2019)

MON-288 TSH Deficiency in Patients on Somatostatin Analog for TSH-PitNET
por: Illouz, Frederic, et al.
Publicado: (2020)

SAT-429 Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers
por: Madan, Ajay, et al.
Publicado: (2019)

OR01-05 Growth Hormone Action In Somatostatin Neurons Regulates Anxiety And Fear Memory
por: dos Santos, Willian O, et al.
Publicado: (2023)

SAT-481 TSH Adenoma: An Elusive Diagnosis
por: Chaudhary, Hira, et al.
Publicado: (2019)

SAT623 Everolimus For Treatment-refractory Prolactinomas
por: Lin, Andrew L, et al.
Publicado: (2023)

SAT-480 Clinical Cases TSH Secreting Adenomas
por: Calasans, Camila, et al.
Publicado: (2019)

SAT-478 Successful Management of an Atypical Prolactinoma with Radiotherapy
por: Bowes, Christa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kiqo3romcb2bgoat6tj1r2j37p